Palmar-plantar erythrodysesthesia

Journal of Oncology Pharmacy Practice

Volumn 9, Issue 4, 2003, Pages 137-150

  Gilbar, Peter ^a  

^a Toowoomba Health Services   (Australia)

Author keywords

Capecitabine; Chemotherapy; Doxorubicin; Fluorouracil; Hand foot syndrome; Palmar plantar erythrodysesthesia

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; 5 ETHYNYLURACIL; ALLOPURINOL; ANTINEOPLASTIC AGENT; CAPECITABINE; CELECOXIB; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOCETAXEL; DOXORUBICIN; EMITEFUR; EMOLLIENT AGENT; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; HYDROXYUREA; LIPOSOME; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; PYRIMIDINE; TEGAFUR; UFT; UNINDEXED DRUG; VINCRISTINE;

ANALGESIA; BLISTER; CLINICAL FEATURE; CONTINUOUS INFUSION; CRYOTHERAPY; DATA BASE; DESQUAMATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG FORMULATION; DRUG MEGADOSE; DYSESTHESIA; ERYTHEMA; HAND FOOT SYNDROME; HUMAN; MEDLINE; MOTOR DYSFUNCTION; PAIN; PARESTHESIA; PRIORITY JOURNAL; PUBLICATION; RETROSPECTIVE STUDY; REVIEW; SKIN TINGLING; SKIN TOXICITY; SYMPTOM; ULCER; WOUND CARE;

EID: 0345328799     PISSN: 10781552     EISSN: None     Source Type: Journal    
DOI: 10.1191/1078155203jp114oa     Document Type: Review

References (103)

1. Baack BR, Burgdorf WHC. Chemotherapy-induced acral erythema. J Am Acad Dermatol 1991; 24: 457-61.
2. Samuels-Reid JH. Common problems in sickle cell disease. Am Fam Physician 1994; 49: 1477-86.
3. Burgdorf WHC, Gilmore WA, Ganick RG. Peculiar acral erythema secondary to high-dose chemotherapy for acute myelogenous leukemia. Ann Intern Med 1982; 97: 61-62.
4. Silver FS, Espinosa LR, Hartmann RC. Acral erythema and hydroxyurea. Letter. Ann Intern Med 1983; 98: 675.
5. Lokich JJ, Moore C. Chemotherapy-associated palmar-plantar erythrodysesthesia syndrome. Ann Intern Med 1984; 101: 798-800.
6. Baer MR, King LE, Wolff SN. Palmar-plantar erythrodysesthesia and cytarabine. Letter. Ann Intern Med 1985; 3102: 556.
7. Peters WG, Willemze R. Palmar-plantar skin changes and cytarabine. Letter. Ann Intern Med 1985; 103: 303-304.
8. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica 1974; 148: 90-92.
9. Meta-Analysis Group in Cancer. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. J Clin Oncol 1998; 16:3537-41.
10. Lotem M, Hubert A, Lyass O, Goldenhersh MA et al. Skin toxic effects of polyethylene glycol-coated liposomal doxorubicin. Arch Dermatol 2000; 136: 1475-80.
11. Blum JL, Jones SE, Busdar AU, LaRusso PM et al. Multicenter Phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999; 17: 485-93.
12. Prussick R. Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy. Sem Cutan Med Surg 1996; 15: 267-76.
13. Kroll SS, Koller CA, Kaled S, Dreizen S. Chemotherapy-induced acral erythema: desquaminating lesions involving hands and feet. Ann Plast Surg 1989; 23: 263-65.
14. Fitzpatrick JE. Perspectives in dermatology. The cutaneous histopathology of chemotherapeutic reactions. J Cutan Pathol 1993; 20: 1-14.
15. Tsuruta D, Mochida K, Hamada T, Ishii M et al. Chemotherapy-induced acral erythema: report of a case and immunohistochemical findings. Clin Exp Dermatol 2000; 25: 386-88.
16. Crider MK, Jansen J, Norins AL, McHale MS. Chemotherapy-induced acral erythema in patients receiving bone marrow transplantation. Arch Dermatol 1986; 122: 1023-27.
17. Kerker BJ, Hood AF. Chemotherapy-induced cutaneous reactions. Semin Oncol 1989; 8: 173-81.
18. Azurdia RM, Clark RE, Friedmann PS. Chemotherapy-induced acral erythema (CIAE) with bullous reaction. Clin Exp Dermatol 1999; 24: 64-66.
19. Budman DR, Meropol NJ, Reigner B et al. Preliminary studies of a novel oral fluoroprimidine carbamate: capecitabine. J Clin Oncol 1998; 16: 1795-802.
20. Mackean M, Planting C, Twelves C et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol 1998; 16: 2977-85.
21. Van Cutsem E, Findlay M, Osterwalder B et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized Phase II study. J Clin Oncol 2000; 18: 85.
22. Blum JL, Dieras V, Lo Russo PM et al. Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001; 92 1759-68.
23. Hoff PM, Ansari R, Batist G etal. Comparison of oral capecitabine versus intravenous fluororacil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized Phase III study. J Clin Oncol 2001; 19: 2282-92.
24. Van Cutsem E, Twelves C, Cassidy J et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large Phase III study. J Clin Oncol 2001; 19: 4097-106.
25. Abushulliah S, Saas ED, Munsell M, Hoff PM. Incidence and severity of hand-foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience. Cancer Invest 2002; 20: 3-10.
26. Lin EH, Morris J, Chau NK et al. Celecoxib attenuated capecitabine induced hand-and-foot syndrome (HFS) and diarrhea and time to tumor progression in metastatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2002; 21: abstract 2364.
27. Lamont EB, Schilsky RL. The oral fluoropyrimidines in cancer chemotherapy. Clin Cancer Rev 1999; 5:2289-96.
28. Herzig RH, Wolff SN, Lazarus HM, Phillips GL, Karanes C, Herzig GP. High-dose cytosine arabinoside therapy for refractory leukemia. Blood 1983; 62: 361-69.
29. Vakalis D, Ioannides D, Lazaridou E, Mattheou-Vakali G, Teknetzis A. Acral erythema induced by chemotherapy with cisplatin. Br J Dermat 1998; 139-750-51.
30. Matsuyama JR, Kwok KK. A variant of the chemotherapy-associated erythrodysesthesia syndrom related to high-dose cyclophosphamide. DCIP 1989; 23: 776-79.
31. Cordonnier C, Roujeau JC, Vernant JP, Matheron S, Ganem G. Cancer chemotherapy and acral erythema. Letter. Ann Intern Med 1982; 97: 783.
32. Demircay Z, Gurbuz O, Alpdogan TB et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol 1997; 36: 593-98.
33. Kampmann KK, Graves T, Rogers SD. Acral erythema secondary to high-dose cytosine arabinoside with pain worsened by cyclosporine infusions. Cancer 1989; 63: 2482-85.
34. Waltzer JF, Flowers FP. Bullous variant of chemotherapy-induced acral erythema. Letter. Arch Dermatol 1993; 129: 43-45.
35. Hui YF, Cortes JE. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin. Pharmacotherapy 2000; 20: 1221-23.
36. Rarick MU, Gill PS, Wernz JC et al. Dermatological toxicities associated with chemotherapy using liposomal encapsulated daunorubicin (DaunoXome). Proc Am Soc Clin Oncol 1997; 16: abstract 878.
37. Vukelja SJ, Baker WJ, Burris HA, Keeling JH, Von Hoff D. Pridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere. Letter. J Natl Cancer Inst 1993; 85: 1432-33.
38. Zimmerman GC, Keeling JH, Burris HA et al. Acute cutaneous reactions for palmar-plantar erythrodysesthesia associated with taxotere. Letter. J Natl Cancer Inst 1993; 85: 1432-33.
39. Miller KD, McCaskill-Stevens W, Sisk J et al. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: randomized pilot trial of the Hoosier Oncology Group. J Clin Oncol 1999; 17: 3033-37.
40. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination in anthracycline-pretreated patients with advanced breast cancer: Phase III trials results. J Clin Oncol 2002; 20: 2812-23.
41. Vogelzang NJ, Ratain MJ. Cancer chemotherapy and skin changes. Letter. Ann Intern Med 1985; 103: 303-304.
42. Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcomas. Cancer Treat Rep 1987; 71: 971-72.
43. Jones AP, Crawford SM, Anthracycline-induced toxicity affecting palmar and plantar skin. Br J Cancer 1989; 59; 814.
44. Uziely B, Jeffers S, Isacson R et al. Liposomal doxorubicin: antitumour activity and unique toxicities during complementary Phase I studies. J Clin Oncol 1995; 13: 1777-85.
45. Johnston SRD, Gore ME. Caelyx®: Phase II studies in ovarian cancer. Eur J cancer 2001; 37: S8-S14.
46. Gordon KB, Tajuddin A, Guitart J, Kuzel TM, Eramo LR, VonRoenn J. Hand-foot syndrome associated with liposomal-encapsulated doxorubicin therapy. Cancer 1995; 75: 2169-73.
47. Muggia FM, Hainsworth JD, Jeffers S et al. Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumour activity and toxicity modification by liposomal encapsulation. J Clin Oncol 1997; 15: 987-93.
48. Ranson MR, Carmichael J, O'Byrne K, Stewart S, Smith D, Howell A. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter Phase II trial. J Clin Oncol 1997; 15: 3185-91.
49. 2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gyne Oncol 2000; 78: 369-72.
50. Lyass O, Uziely B, Ben-Yosef R et al. Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast cancer. Cancer 2000; 89: 1037-47.
51. Gordon AN, Fleagle JT, Guthrie D, Parkin DE, Gore ME, Lacave AJ. Recurrent epithelial ovarian carcinoma: a randomized Phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-22
52. de Vries EG, Greidanus J, Mulder NH et al. A Phase I and pharmacokinetic study with 21-day continuous infusion of epirubicin. J Clin Oncol 1987; 5: 1445-51.
53. Schey SA, Cooper J, Summerhayes M. The 'handfoot syndrome' occurring with chronic administration of etoposide. Letter. Eur J Haematol 1992; 48: 118-19.
54. Bellmunt J, Navarro M, Hidalgo R, Sole LA. Palmar-plantar erythrodysesthesia syndrome associated with short-term continuous infusion (5 days) of 5-fluorouracil. Tumori 1988; 74: 329-31.
55. Diaz-Rubio E, Aranda E, Martin M, Gonzales-Mancha R, Gonzales-Larriba J, Barneto I. Weekly high-dose infusion of 5-fluorouracil in advanced colorectal cancer. Eur J Cancer 1990; 26: 727-29.
56. Comandone A, Bretti S, La Grotta G et al. Palmar-plantar erythrodysestasia syndrome associated with 5-fluorouracil treatment. Anticancer Res 1993; 13: 1881-784.
57. Lokich JJ, Ahlgren JD, Cantrell J et al. A prospective randomized comparison of protracted infusional 5-fluorouracil with or without weekly bolus cisplatin in metastatic colorectal carcinoma. Cancer 1991; 67: 14-19.
58. Grem JL, McAtee N, Balis F et al. A Phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 1993; 72: 663-68.
59. Fabian CJ, Molina R, Slavik M, Dahlberg S, Giri S, Stephens R. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion. Invest New Drugs 1990; 8: 57-63.
60. Weh HJ, Wilkie HJ, Dierlamm J et al. Weekly therapy with folinic acid (FA) and high-dose 5-fluorouracil (5-FU) 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 1994; 5: 233-37.
61. Chiara S, Nobile MT, Barzacchi C et al. Hand-foot syndrome induced by high-dose, short-term, continuous 5-fluorouracil infusion. Eur J Cancer 1997; 33: 967-69.
62. Cure H, Chevalier A, Adenis A et al. Phase II trial of chronomodulated infusion of high-dose fluorouracil and l-folinic acid in previously untreated patients with metastatic colorectal cancer. J Clin Oncol 2002; 20: 1175-81.
63. Atkins JN. Fluorouracil and the palmar-plantar erythrodysesthesia syndrome. Letter. Ann Intern Med 1985; 102: 419.
64. Vukelja SJ, Lombardo FA, James WD, Weiss RB. Pyridoxine for the palmar-plantar erythrodysesthesia syndrome. Letter. Ann Intern Med 1989; 111: 688-89.
65. Mortimer JE, Anderson I. Weekly fluorouracil and high-dose lecovorin: efficacy and treatment of cutaneous toxicity. Cancer Chemother Pharmacol 1990; 26: 449-52.
66. Curran CF, Luce JK. Fluorouracil and palmar-plantar erythrodysesthesia. Letter. Ann Intern Med 1989; 111: 858.
67. Gilbar P. Palmar-plantar erythrodysesthesia associated with an initial course of bolus fluorouracil. Letter J Pharm Pract Res 2002; 32: 178-79.
68. Diasio RB, Johnson MR. Dihydropyrimidine dehydrogenase: its role in 5-fluorouracil clinical toxicity and tumor resistance. Clin Cancer Res 1999; 5: 2672-73.
69. Jucgla A, Sais G. Palmoplantar Keratoderma secondary to chronic acral erythema due to tegafur. Arch Dermatol 1995; 131: 364-65.
70. Elasmar SA, Saad ED, Hoff PM. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1. Jap J Clin Oncol 2001; 31: 172-74.
71. Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/leucovorin (ORZEL™) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000; 18: 331-42.
72. Smith IE, Johnston SRD, O'Brien MER et al. Low-dose oral fluorouracil with enuracil as first-line chemotherapy against advanced breast cancer: a phaseII study. J Clin Oncol 2000; 18: 2378-84.
73. Silver FS, Espinooza LR, Hartmann RC. Acral erythema and hydroxyurea. Letter. Ann Intern Med 1983; 98: 675.
74. Vassallo C, Passamonti F, Merante S et al. Mucocutaneous changes during long-term therapy with hydroxyurea in chronic myeloid leukaemia. Clin Exp Dermatol 2001; 26: 141-48.
75. Cox GJ, Robertson DB. Toxic erythema of palms and soles associated with high-dose mercaptopurine chemotherapy. Arch Dermatol 1986; 122: 1413-14.
76. Balis FM. Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokinet 1986; 11: 223-35.
77. Doyle LA, Berg C, Bottino G, Chabner B. Erythema and desquamination after high-dose methotrexate. Ann Intern Med 1983; 98: 611-12.
78. Ro YS, Kim JH, Kim JH. Chemotherapy-induced acral erythema showing vasculitis histologic features. Letter. Arch Dermatol 1991; 127: 1588-89.
79. Chang JC. Acute bullous dermatosis and onycholysis due to high-dose methotrexate and leucovorin calcium. Letter. Arch Dermatol 1987; 123: 990-92.
80. Ikeda H, Kawano H, Kitaura T, Kimura A, Kihira K. Acral erythema associated with high-dose methotrexate infusion. Letter. Ann Pharmacother 1999; 33: 646.
81. Martins da Cuhna AC, Rappersberger K, Gadner H. Toxic skin reaction restricted to palms and soles after high-dose methotrexate. Pediatr Hematol Oncol 1991; 8: 277-80.
82. Hellier I, Bessis D, Sotto A, Margueritte G, Guilhou JJ. High-dose methotrexate-induced bullous variant of acral erythema. Arch Dermatol 1996; 132; 590-91.
83. Millot F, Auriol F, Brech P, Guilhot F. Acral erythema in children receiving high-dose methotrexate. Pediatr Dermatol 1999; 16: 398-400.
84. Morrell DS, Challgren E, Eapen M, Esterly NB. Bullous acral erythema secondary to high-dose methotrexate. Letter. J Pediatr Hematol Oncol 2002; 24: 240.
85. de Arglia D, Dominguez JD, Iglesias L, Taxol-induced acral erythema. Dermatology 1996; 192: 377-78.
86. Merimsky O, Inbar MJ. Herceptin-Taxol related hand and foot syndrome. IMAJ 2000; 2: 786.
87. de Bono JS, Stephenson J, Baker SD et al. Troxacitabine, an L-stereoisomeric nucleoside analog, on a five-times-daily schedule: a Phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol 2001; 20: 96-109.
88. Giles FJ, Cortes JE, Baker SD et al. Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia. J Clin Oncol 2001; 19: 762-71.
89. Giles FJ, Garcia-Manero G, Cortes JE et al. Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia. J Clin Oncol 2002; 20: 656-64.
90. Hoff PM, Valero V, Ibrahim N, Willey J, Hortobagyi GN. Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. Cancer 1998; 82: 965-69.
91. Ibrahim NK, Valero V, Theriault RL et al. Phase I study of vinoreline by 96-hour infusion in advanced metastatic breast cancer. Am J Clin Oncol 2000; 23: 117-21.
92. Toussaint C, Izzo J, Spielmann M et al. Phase I/II trial of continuous infusion vinorelbine for advanced breast cancer. J Clin Oncol 1994; 12: 2102-12.
93. Zimmerman GC, Keeling JH, Lowry M, Medina J, Von Hoff DD, Burris HA. Prevention of docetaxel-induced erythrodysesthesia with local hypothermia. Letter. J Natl Cancer Inst 1994; 86: 557-58.
94. Brown J, Burck K, Black D, Collins C. Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 1991; 6: 1023-25.
95. Walker IR, Wilson WEC, Sauder DN, Benger AM, Browman G. Cytarabine-induced palmar-plantar erythema. Letter. Arch Dermatol 1985; 121: 1240-41.
96. Patel JS. Pyridoxine for hand-foot syndrome. Hosp Pharm 1999; 34: 604-605, 609.
97. Lauman MK, Mortimer J. Effect of pyridoxine on the incidence of palmar plantar erythroderma (PPE) in patients receiving capecitabine. Proc Am Soc Clin Oncol 2001; 20: abstract 1565.
98. Vail DM, Chun R, Thamm DH, Garrett LD, Cooley AJ, Obradovich JE. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: a randomized, doubleblind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567-71.
99. Wiernik PH, Yeap B, Vogl SE et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992; 10: 1-9.
100. Bertelli G, Gozza A, Forno GB et al. Topical dimethyl-sulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995; 13: 2851-55.
101. Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM, Alberts DS. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythro-dysesthesia. Cancer Chemother Pharmacol 1999; 44: 303-306.
102. Anon. Xeloda (Capecitabine) product monograph. Dee Why. Australia: Roche Products Ltd, 1999.
103. Anon. Caelyx (Liposomal Doxorubicin). Baulkham Hills, Australia: Schering-Plough Pty Ltd, 2001.